Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Experimental cancer drugs
Marimastat
Другие языки:

    Marimastat

    Подписчиков: 0, рейтинг: 0
    Marimastat
    Marimastat.svg
    Clinical data
    Routes of
    administration    		 By mouth
    ATC code
    • None
    Legal status
    Legal status
    • Development terminated?
    Identifiers
    • N-[2,2-Dimethyl-1-(methylcarbamoyl)propyl]-2-[hydroxy-(hydroxycarbamoyl)methyl]-4- methyl-pentanamide
    CAS Number
    PubChem CID
    IUPHAR/BPS
    DrugBank
    ChemSpider
    UNII
    ChEMBL
    PDB ligand
    CompTox Dashboard (EPA)
    Chemical and physical data
    Formula C15H29N3O5
    Molar mass 331.413 g·mol−1
    3D model (JSmol)
    • O=C(NO)[C@@H](O)[C@H](C(=O)N[C@H](C(=O)NC)C(C)(C)C)CC(C)C
    • InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1 ☒N
    • Key:OCSMOTCMPXTDND-OUAUKWLOSA-N ☒N
     ☒NcheckY (what is this?)  (verify)

    Marimastat was a proposed antineoplastic drug developed by British Biotech. It acted as a broad-spectrum matrix metalloproteinase inhibitor.

    Marimastat performed poorly in clinical trials, and development was terminated. This may be, however, a result of targeting cancer at too late of a stage. This is supported by the fact that MMP inhibitors have more recently been shown in animal models to be more effective in earlier stages of cancers. (Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284, 808-812. Bergers, G., Javaherian, K., Lo, K.-M., Folkman, J., and Hanahan, D. (1999)).

    See also



    Новое сообщение